Sunny Pharmtech Past Earnings Performance
Past criteria checks 0/6
Sunny Pharmtech has been growing earnings at an average annual rate of 18.6%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 12.3% per year.
Key information
18.6%
Earnings growth rate
23.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 12.3% |
| Return on equity | -5.3% |
| Net Margin | -14.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sunny Pharmtech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 429 | -63 | 149 | 209 |
| 30 Sep 23 | 405 | -90 | 147 | 224 |
| 30 Jun 23 | 382 | -116 | 145 | 240 |
| 31 Mar 23 | 371 | -143 | 142 | 248 |
| 31 Dec 22 | 360 | -170 | 138 | 256 |
| 30 Sep 22 | 317 | -176 | 136 | 226 |
| 30 Jun 22 | 274 | -182 | 133 | 197 |
| 31 Mar 22 | 257 | -179 | 127 | 184 |
| 31 Dec 21 | 241 | -175 | 120 | 171 |
| 30 Sep 21 | 277 | -162 | 117 | 175 |
| 30 Jun 21 | 312 | -150 | 113 | 178 |
| 31 Mar 21 | 366 | -126 | 115 | 180 |
| 31 Dec 20 | 420 | -102 | 116 | 182 |
| 30 Sep 20 | 426 | -112 | 114 | 187 |
| 30 Jun 20 | 432 | -121 | 111 | 192 |
| 31 Mar 20 | 333 | -174 | 107 | 199 |
| 31 Dec 19 | 234 | -226 | 104 | 206 |
| 30 Sep 19 | 194 | -260 | 103 | 251 |
| 30 Jun 19 | 153 | -295 | 103 | 296 |
| 31 Mar 19 | 148 | -297 | 111 | 301 |
| 31 Dec 18 | 143 | -300 | 119 | 305 |
Quality Earnings: 6676 is currently unprofitable.
Growing Profit Margin: 6676 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6676 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare 6676's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6676 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 6676 has a negative Return on Equity (-5.28%), as it is currently unprofitable.